

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 8-K

Valeant Pharmaceuticals International, Inc.

Form 8-K

February 03, 2011



**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

Signatures

EXHIBIT INDEX

EX-99.1

---

**Table of Contents**

**Item 8.01 Other Events.**

Valeant Pharmaceuticals International ( Valeant ), a wholly owned indirect subsidiary of Valeant Pharmaceuticals International, Inc., plans to offer approximately \$650 million aggregate principal amount of senior unsecured notes. The notes will be offered in the United States to qualified institutional investors under Rule 144A of the Securities Act of 1933, as amended (the Securities Act ), and to certain non-U.S. persons in transactions outside the United States under Regulation S of the Securities Act.

The foregoing is qualified by reference to the press release that is attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

This Current Report on Form 8-K, including the press release filed as Exhibit 99.1, does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any state in which such offer, solicitation or sale would be unlawful. These securities will not be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit**

**Number      Description**

99.1              Press Release announcing the launch of the offering, dated February 3, 2011

---

**Table of Contents**

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS  
INTERNATIONAL, INC.,

By: /s/ Robert Chai-Onn

Name: Robert Chai-Onn

Title: Executive Vice President, General  
Counsel and Corporate Secretary

February 3, 2011

---

**Table of Contents**

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Press Release announcing the launch of the offering, dated February 3, 2011